Use of dextran in adult patient undergoing liver transplantation

In this study we will use patient data from a single centre to investigate the association of intravenous dextran infusion with thrombotic complications such as hepatic artery thrombosis and portal vein thrombosis, in adult patients undergoing liver transplantation. In using routinely collected in-hospital data, this study will also identify independent risk factors for thrombotic complications in patients receiving dextran, as well as post-operative complications including (but not limited to) mortality, length of stay, and new co-morbidities. There is no direct patient involvement, only the retrospective collection of patient data from their electronic medical records and there Each patients' data will only be collected once and the period for which the data will be collected will from the start of their liver transplant surgery (surgical incision) to their date of hospital discharge. All patients who underwent liver transplantation and intravenous dextran between 1st January 2014 to 29 February 2024 will have their data collected. There will be no prospective collection of any other data. Patients will not be contacted at any point. The types of data collected will be data-linkage only. From the data collected from the electronic medical records, we will describe the baseline characteristics of those liver transplant patients who received intravenous dextran. We will seek to summarise their intraoperative course and collect data on their postoperative outcomes, including complications.